U.S. biotechnology company Novavax, via Nucleus Network, began injecting 6 Australian volunteers with their nanoparticle encapsulated “spike” protein recombinant coronavirus vaccine candidate (Novavax NVX-CoV2373) in Melbourne on Tuesday 26 May 2020. [1, 2, 3]
Novavax trials received funding support from CEPI.